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Summary Serum levels were determined in 434 patients with benign and malignant gastrointestinal diseases
and compared with the serum concentrations of carcinoembryonic antigen (CEA) and alpha-fetoprotein
(AFP). The highest proportion of elevated CA-S0 levels (>17 Uml-1) was found in patients with pancreatic
cancer (73%). High levels were mainly associated with advanced cancer, but also half of the patients with a
resectable pancreatic tumour had an increased CA-S0 concentration. The CA-S0 level was elevated in 37-58%
of patients with colorectal, gastric, hepatocellular and biliary tract cancers. In all gastrointestinal cancers, CA-
50 gave additional information compared with CEA and AFP, except in hepatocellular carcinoma where AFP
was the best marker.
Carcinoembryonic antigen (CEA) and alpha-fetoprotein
(AFP) are well established tumour markers for gastro-
intestinal malignancies. The serum CEA level is elevated in a
large proportion of patients with gastrointestinal and in part
of non-gastrointestinal cancers, but also in patients with
various benign diseases (Zamcheck et al., 1972). Therefore it
is not suitable as a marker for primary diagnosis but it is
valuable in the follow-up of cancer patients with an elevated
CEA level prior to therapy (Cooper et al., 1979). Alpha-
fetoprotein is a good tumour marker in the diagnosis of
hepatocellular carcinomas and yolk sack tumours. Even
small localized tumours cause elevation of the marker level
(Ruoslahti & Seppailii, 1979).
A new tumour-associated antigen, CA-50, is defined by a
monoclonal antibody raised against a colorectal carcinoma
cell line (Lindholm et al., 1983). The C-50 antibody reacts
not only with a sialylated Lewisa-blood group substance but
also with another carbohydrate structure, sialosyl-
lactotetraose, which lacks the fucosyl residue present in the
sialylated Lewisa_structure (Nilsson et al., 1985; Mansson et
al., 1985).
The CA-50 antigen is found in serum in a high molecular
weight glycoprotein fraction and on cell surfaces in ganglio-
sides (Lindholm et al., 1983, 1985). High serum CA-50
concentrations were originally observed in a large propor-
tion of patients with gastrointestinal cancers, especially
pancreatic cancer, and also in some non-gastrointestinal
malignancies such as lung, bladder and gynaecological
cancers (Holmgren et al., 1984).
The aim of this study was to evaluate the usefulness of
CA-50 in the diagnosis of gastrointestinal cancers. Serum
levels of CA-50 were determined in patients with malignant
and benign diseases of the colon, stomach, liver, pancreas
and biliary tract and compared with the CEA and AFP
concentrations.
Materials and methods
Patients
The serum levels of CA-50 were measured in 244 patients
with gastrointestinal cancers and in 190 patients with benign
gastrointestinal diseases. In patients with carcinomas the
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serum samples were taken pre-operatively and in patients
with carcinoma recidives at the time of verification of the
recurrence. Patients receiving chemotherapy were excluded.
The diagnoses were based on histological or cytological
findings and on clinical and laboratory records:
Colorectal diseases Colorectal carcinomas (57 primary and
35 recurrent tumours). Benign diseases (33 patients)
consisted of colorectal polyposis, benign adenomas,
diverticulosis, ulcerative colitis and Crohn's disease.
Gastric diseases Gastric cancer (39 patients), benign gastric
diseases (63 patients) including gastric or duodenal ulcer and
chronic gastritis.
Liver diseases Hepatocellular carcinoma (11 patients),
benign liver diseases (21 patients) including cirrhosis, acute
hepatitis and chronic persistent hepatitis.
Biliary tract diseases Cholangiocarcinoma (12 patients),
cholelithiasis with or without jaundice (26 patients).
Pancreatic diseases Pancreatic cancer (8 resectable and 82
locally spread or metastasized carcinomas), acute and
chronic pancreatitis (47).
Assays
CA-50 was quantitated either by the CanAg CA-50 RIA
inhibition test (Stena Diagnostics, Gothenburg, Sweden) or,
in part of the samples, by an immunoradiometric (IRMA)
assay. In the IRMA test the CA-50 antigen in the sample
binds first on polystyrene beads coated with monoclonal C-
50 antibody (catcher antibody) and is then detected with a
iodinated form of the same antibody (detecting antibody).
The cut-off level of 17Uml-1 representing the mean+2 s.d.
of normal individuals in the RIA test (Stena Diagnostics)
was used for both assays.
The serum CEA concentration was measured by a double
antibody assay (Rutanen et al., 1978), where CEA-antiserum
(Dakopatts a/s Copenhagen, Denmark) was used as the first
antibody, or measured by the Abbot-CEA-RIA Diagnostic
Kit (Abbot, Wiesbahn, West Germany). The two assays
showed a good correlation (r2=0.9997; Jalanko et al., 1984).
Alpha-fetoprotein was measured by a double antibody assay
(Ruoslahti & Seppiilii, 1971). The cut-off levels of
2.5ngml-1 and 25ngml-1 were used for the CEA- and
AFP-measurements, respectively.
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Results
Colorectal diseases
In patients with primary colorectal carcinoma, elevated
(> 17Uml-1) CA-50 values were found in 37% (Table I and
II). The highest level was 16,000 Uml-1. Recurrence of the
disease caused elevation of CA-50 in 49% of the patients
(range: 2-1970 Uml-1) (Figure 1, Table I). Elevated values
were mainly seen in advanced diseases (Dukes' C and D),
whereas only 4 out of 18 local cancers (Dukes' A and B)
showed an increase of the marker concentration. A slightly
elevated CA-50 value (up to 42Uml-P) was found in two
out of 33 patients (6%) with benign colorectal diseases
(Table I).
Carcinoembryonic antigen was elevated (>2.5ngml-') in
67% of the patients with colorectal carcinoma (primary and
recurrent) and in 21% of the patients with benign colorectal
disease (Table I and II). No correlation was found between
the CA-50 and CEA concentrations (Figure 1). Twenty-eight
percent of the cancer patients had a CA-50 level higher than
any patient with benign colorectal disease. The
corresponding percentage for CEA was 41%. Elevated
values of both CA-50 and CEA were found in 36% of the
Table I CA-50, CEA and AFP in gastrointestinal disease
Elevated values (%)
Disease No. CA-50a CEAb AFPC
Colon ca 57 21 (37) 32 (56) ND
Colon ca recid. 35 17 (49) 30 (86) ND
Benign colon dis. 33 2 (6) 7 (21) ND
Gastric ca 39 16 (41) 12 (31) ND
Benign gastric dis. 63 9 (15) 10 (16) ND
Liver ca 11 6 (55) ND 9 (82)
Benign liver dis. 21 9 (43) ND 2 (10)
Biliary tract ca 12 7 (58) ND 1 (8)
Benign biliary tract dis. 26 10 (39) ND 0 (0)
Pancreatic ca 90 66 (73) 48 (53) ND
Benign pancreatic dis. 47 ' 10 (21) 11 (23) ND
a> 17Uml-1; b>2.5ngml 1; c>25ngml-l; ND: not determined.
10 000
1000 -
100i
10-
1
-
A
0
A
A
*A
A
i
A
A
S0
A A
0
0
A
A -
* 0
..A *0
1, 0 A A A
A AAj~~~~~~0
OS A
AAc 0 0
0I 1 10 100
CEA (ng ml-1)
1000
Figure 1 Comparison of the CA-50 and CEA levels in patients
with colon cancer (0), recidives of colon cancer (A) and with
benign colorectal diseases (0).
Table II Assay parameters
CA-50+
Thmour origin CA-50+a CEA+b AFP+C or CEA +/
AFP+
Colorectal
New cancers
sensitivity' 37 56 NDh 65
specificity' 94 79 ND 76
pos. pred. value' 91 82 ND 82
neg. pred. valueg 46 50 ND 56
Recidives
sensitivity 49 86 ND 89
specificity 94 79 ND 76
pos. pred. value 90 81 ND 80
neg. pred. value 63 84 ND 86
New cancers+recidives
sensitivity 41 67 ND 74
specificity 94 79 ND 76
pos. pred. value 95 84 ND 90
neg. pred. value 27 46 ND 51
Gastric
sensitivity 41 31 ND 51
specificity 86 84 ND 75
pos. pred. value 64 55 ND 56
neg. pred. value 70 66 ND 71
Liver
sensitivity 55 ND 82 82
specificity 50 ND 89 44
pos. pred. value 40 ND 82 47
neg. pred. value 64 ND 89 80
Biliary tract
sensitivity 58 ND 8 73
specificity 62 ND 100 62
pos. pred. value 41 ND 100 44
neg. pred. value 76 ND 70 80
Pancreas
sensitivity 73 53 ND 81
specificity 79 77 ND 62
pos. pred. value 87 81 ND 80
neg. pred. value 61 46 ND 63
a>17UmlP1; b>2.5ngml-'; c>25ngml-i; dTP/(TP+
FN) x 100; 'TN/(TN+FP) x 100; fTP/(TP+FP) x 100;
'TN/(TN +FN) x 100; hND: not determined; TP=true positive; TN
=true negative; FP=false positive; FN =false negative.
cancer patients. The combination of elevated CA-50 and
normal CEA was seen in 7% of these patients, while the
percentage for the opposite combination was 35%
(Figure 1).
Gastric diseases
The CA-50 level was elevated in 41% of the patients with
gastric cancer (range: 4-1,450Uml-1), whereas benign
gastric diseases were associated with an increased
concentration in 9 out of 63 patients (15%; range; 0-288
Uml-1) (Figure 2, Table I).
Elevated CEA levels were found in 31% of the patients
with gastric cancer and in 16% of the patients with benign
gastric diseases (Figure 2; Table I). No correlation was
observed between the CA-50 and CEA levels (Figure 2).
Liver and biliary tract diseases
More than half of the patients with hepatic (55%) or biliary
tract (58%) cancers had CA-50 levels above the cut-off value
°°° of 17Uml-1 (Figure 3, Table I). Elevated CA-50 levels were
also seen in almost half of the patients with benign hepatic
diseases (43%) and in one third of the patients with benign
biliary tract diseases (38%), especially in extrahepatic
cholestasis and biliary tract infections. There was no
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Figure 2 Comparison of the CA-50 and CEA levels in patients
with gastric cancer (0) and benign gastric diseases (0).
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Figure 3 Comparison of the CA-50 and AFP levels in patients
with hepatocellular cancer (0) and biliary tract cancer (A) and
with benign hepatocellular (0) and biliary tract diseases (A).
correlation between the CA-50 values and the serum
concentrations of alkaline phosphatase or bilirubin (data not
shown).
AFP was elevated (>25 ngml1) in 82% of the patients
with hepatic cancer but in only 8% of the patients with
biliary tract cancer (Figure 3, Table I). There was no
correlation between the CA-50 and AFP concentrations in
these patients (Figure 3).
Pancreatic diseases
An increased serum CA-50 concentration was found in 73%
Figure 4 Comparison of the CA-50 and CEA levels in patients
with pancreatic cancer (U localized, 0 advanced) and benign
pancreatic diseases (0).
of the patients with pancreatic cancer (Figure 4; Table I).
The highest values (up to 68,000Uml-1) were seen in
patients with advanced tumours, but also 5 out of 8 patients
with a resectable pancreatic tumour had an elevated marker
level (Figure 4). Slightly or moderately elevated values (up to
145Uml-1) were also found in 21% of the patients with
benign pancreatic diseases (Figure 4; Table I). Almost half of
the patients with pancreatic cancer (45%) had a marker level
higher than any of the patients with benign pancreatic,
biliary tract or liver diseases (Figures 3 & 4). The CEA level
was elevated in 53% of the patients with pancreatic cancer
and in 23% of the patients with benign pancreatic diseases
(Table I). No correlation was observed between the CA-50
and CEA concentrations in these patients (Figure 4).
Discussion
The highest proportion of elevated CA-50 levels was found
in patients with pancreatic cancer, of which 73% had a CA-
0° 50 concentration higher than 17Uml-1. The CEA level was
above 2.5ngml-1 in 53% of these patients, and 32% had a
CEA level higher than 10ngml-1. The better sensitivity of
the CA-50 assay was further confirmed by the finding that 5
out of 8 patients with a resectable carcinoma had an elevated
CA-50 level, but only two of 8 patients had an elevated CEA
value (>2.5ngml-1). The major problem in using the CA-
50 test in the diagnosis of pancreatic cancer was the high
percentage of false positive values in patients with
extrahepatic cholestatis of benign origin. In clinical practise a
threshold concentration of 70Uml- I could be used for
evaluating the CA-50 values of patients with a normal
bilirubin level, whereas a higher cut-off value of about
200 Uml-1 should be used for patients with elevated
bilirubin values.
The CA-50 test seems to give little additional information
compared to the CEA assay in patients with colorectal
carcinoma. Only 9% of the patients with primary carcinoma
and 3% of the patients with recurrent disease could be
detected solely by CA-50, whereas the corresponding percen-
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tages for CEA were 28% and 40%, respectively. The com-
bined use of CA-50 and CEA in primary diagnosis of
colorectal cancer is favoured by the better specificity of the
CA-50 test, as only 2 out of 33 patients with benign
colorectal disease showed a slightly elevated CA-50 level. In
recurrent diseases the combined use of the assays gives no
additional information compared with CEA alone.
The present results confirm that AFP is superior to CA-50
in detecting liver carcinomas. In this cancer group CA-50
seems to have no practical use.
Alpha-fetoprotein is very seldom elevated in patients with
biliary tract carcinomas, whereas CA-50 detects more than
half (58%) of these patients. The value of a better sensitivity
of the CA-50 test is impaired by the poor specificity (62%).
This is due to high marker levels found in patients with
jaundice and biliary tract inflammation. However, by com-
bining these markers the sensitivity can be increased to 73%
without decreasing the specificity.
Both the CA-50 and CEA assays have a low sensitivity for
gastric carcinoma, although the CA-50 assay detects 10%
more carcinomas than CEA.
The utility of CA-50 as a tumour marker in clinical
practice still has to be evaluated. In our experience, CA-50 is
valuable in the diagnosis and follow-up of patients with
pancreatic cancer (Haglund et al., 1987). In this cancer
group, CA-50 seems to correlate well with CA-19.9
(Koprowski et al., 1979), another new tumour marker re-
lated to CA-50. Experiments are in progress to study the
correlation of these two tumour antigens also in other
gastrointestinal cancers. The present results, however, in-
dicate that CA-50, in combination with old tumour markers,
can give additional information in patients with colorectal,
gastric or biliary tract cancer.
The authors thank Dr Leif Lindholm (Stena Diagnostics) for
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